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Throughout his post-transplant course, he had elevated low-density lipoprotein (LDL) cholesterol (Ͼ130 mg/dL). He was prescribed 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, but he took these irregularly, complaining that they caused bloating and nausea. Fasting triglycerides were generally Ͻ200 mg/dL, and the highdensity lipoprotein (HDL) cholesterol was low (Ͻ35 mg/dL) on several occasions. Lipoprotein(a) also was elevated (Ͼ30 mg/dL). He began taking an aspirin, 325 mg daily, after his first myocardial infarction, and he continued taking aspirin throughout his posttransplant course. He continued to smoke 1 1 ⁄ 2 packs of cigarettes per day; his fasting blood glucose was always normal. His blood pressure was well controlled with
CASE PRESENTATION
antihypertensive medications that included beta-blockers and A 33-year-old man received a haplo-identical kidney transconverting enzyme inhibitors. plant from his brother in 1979. He had had proteinuria for Twenty years after transplantation he had an acute rise in 16 years prior to transplantation, and his renal disease was serum creatinine, but an allograft biopsy showed only mild attributed to chronic glomerulonephritis. He had developed chronic allograft nephropathy, and his immunosuppressive reghypertension 10 years before transplantation. He started mainimen (azathioprine and prednisone) was not changed. He detenance hemodialysis 6 months before transplantation, and veloped intermittent atrial fibrillation, which was treated with after initiating hemodialysis he underwent bilateral nephrecrepeated cardioversion and warfarin. Ultimately, he developed tomy and splenectomy. In that same month he was hospitalized severe congestive cardiomyopathy, and his name was placed with chest pain, and a myocardial infarction was ruled out. He on the waiting list for a heart transplant shortly before he died, had no clinical signs and symptoms of ischemic heart disease 21 years after renal transplantation. Just before he died, his (IHD); however, he had smoked 1 1 ⁄ 2 packs of cigarettes daily serum creatinine was 1.8 mg/dL, his creatinine clearance was for approximately 7 years. He was not obese and his physical 53 mL/min, and he had 506 mg/day of protein in his urine. examination was unremarkable. An electrocardiogram and chest radiograph were normal.
After transplantation he was treated with azathioprine and a history, physical examination, chest radiograph, and
Angiography disclosed occlusions of all 3 bypass grafts and electrocardiogram, all of which were unremarkable. Nevdiffuse underlying coronary artery disease. He had a 2-vessel ertheless, it is likely that the myocardial infarction three coronary artery bypass operation and remained symptom free months after transplantation resulted from coronary artery disease already present at the time of transplanta-
The Nephrology Forum is funded in part by grants from Amgen, serving his life with a functioning transplant for more tion) are equally safe and effective in renal transplant recipients. Having established the link between the risk than 20 years.
The past quarter-century has been a remarkable pefactor and IHD, and having defined therapy that safely modifies the risk factor, we must make a "leap of faith" riod for the development of effective immunosuppressive medications in renal transplantation. Current immuthat the reduction in IHD in the general population also occurs in renal transplant recipients. nosuppression protocols have dramatically reduced the rate of early acute rejection and have substantially imScreening for ischemic heart disease proved one-year graft survival rates. Indeed, death with a functioning allograft now competes with rejection as Pre-transplant IHD is an important risk factor for post-transplant IHD [2, 3] . In a study at the University the most common cause of "renal allograft failure," especially in the late post-transplant period. While the goal of Minnesota, asymptomatic diabetic patients who had significant coronary artery disease (one or more lesions of transplantation is to have every patient die with a functioning kidney transplant, deaths after renal transwith Ͼ70% occlusion) were randomly allocated to medical management or revascularization prior to transplantaplantation still occur much sooner than those of ageand gender-matched patients without renal failure [1] .
tion. Those who underwent revascularization with either angioplasty or bypass surgery had significantly fewer IHD Deaths due to infection and malignancies contribute to this increased mortality rate. However, the leading cause events after transplant surgery [2] . This study suggested that some high-risk, asymptomatic patients would benefit of death after renal transplantation is cardiovascular disease. Thus, further improvement in long-term renal allofrom screening and pre-emptive treatment of IHD. Most transplant centers do not use coronary angiography to graft survival will depend in large part on our ability to reduce deaths from IHD. Although atherosclerotic screen all high-risk transplant candidates. Angiography is not only invasive and costly, but it also can accelerate cardiovascular disease (CVD) also causes morbidity and mortality from cerebral vascular disease and peripheral the patient's need to initiate dialysis [4] . Most centers therefore rely on noninvasive cardiac stress testing to vascular disease, the management of risk factors for IHD will most likely reduce the risk for other atherosclerotic identify asymptomatic patients who need angiography. The American Society of Transplantation (AST) recom-CVD complications as well.
The last 25 years also have been a remarkable period mends that patients at high-risk, that is, diabetics, older individuals defined as more than 40 to 45 years of age, for the development of effective strategies for reducing the morbidity and mortality of IHD. Large, randomized, and individuals with two or more cardiac risk factors, undergo a cardiac stress test as part of the pre-transplant controlled trials in the general population have helped define the roles of risk-factor intervention with antihyperevaluation [5] . The role of post-transplant screening for IHD is poorly defined. tensive medications, lipid-lowering agents, aspirin prophylaxis, and other measures in reducing IHD. Of course, Risk factors for ischemic heart disease these trials have excluded patients with renal disease, and it is unlikely that adequately powered, randomized, Hypertension. The evidence that the pharmacologic treatment of hypertension effectively reduces both stroke controlled trials will ever be conducted to confirm the effectiveness in renal transplant recipients of each of the and IHD in the general population is incontrovertible. In a meta-analysis published in 1990, Collins and coworkers interventions already tested in large multicenter trials in the general population. Therefore, clinicians must decide combined the results from 14 randomized trials that compared the use of diuretics and/or beta-blockers to plawhat evidence can be used to assess which of the therapies effective in the general population should be applied cebo. Over a mean treatment duration of 5 years, they found a 35% to 40% reduction in stroke and a 20% to to renal transplant recipients.
A reasonable approach might be to first establish that 25% reduction in coronary heart disease [6]. Evidence from randomized trials such as these led to the develthe relationship between a particular risk factor and IHD is similar in the renal transplant population to that in opment of guidelines that recommend treatment of hypertension, with blood pressure thresholds tailored to the general population. The relationship might not be the same if, for example, other pathogenetic factors unique to overall IHD risk, using diuretics and beta-blockers as first-line agents [7] . More recently, interest has shifted renal transplant recipients superseded other traditional risk factors in the development of atherosclerotic IHD.
to determining whether newer antihypertensive agents are as good or better at reducing IHD than diuretics and Therefore, one must establish that traditional, modifiable risk factors are independently associated with IHD beta-blockers. A recent meta-analysis of trials comparing the effect of angiotensin-converting enzyme (ACE) inevents in renal transplant recipients, just as they are in the general population. Similarly, it is also important to hibitors with placebo reported a 30% reduction in stroke and a 20% reduction in coronary heart disease despite determine that therapies proven to modify these risk factors (and to reduce the risk of IHD in the general populaonly a 3 mm Hg reduction in systolic blood pressure [8] . transplant recipients, and there are no medications for which there are absolute contraindications. However, Hypertension is common after renal transplantation. The use of calcineurin inhibitors, cyclosporine A (CsA), some adverse effects of medications are more common in renal transplant recipients. Diuretics can raise the serum and tacrolimus; the use of corticosteroids; the presence of native kidneys; and renal allograft dysfunction (including creatinine level in transplant patients. The ACE inhibitors also occasionally raise serum creatinine, but more renal artery stenosis) all likely contribute to the high prevalence of post-transplant hypertension. In patients often ACE inhibitors cause mild hyperkalemia, and they can contribute to anemia. Calcium channel blockers probtreated with azathioprine and prednisone, the prevalence of hypertension is 50% to 70% [11] . The prevalence in ably should be used with caution, at least as monotherapy [16] . Some calcium channel blockers increase blood levpatients treated with CsA is 65% to 85% [11] .
Few studies have examined the relationship between els of cyclosporine. Given the prevalence of IHD, betablockers and ACE inhibitors are particularly attractive blood pressure and IHD after renal transplantation. However, in 29,751 transplant recipients in the Collaborative for renal transplant recipients. In the end, more than half of transplant recipients need combination therapy Transplant Study, hypertension was associated with both decreased graft and patient survival [12] . Unfortunately, to adequately control blood pressure. Hyperlipidemia. Randomized controlled trials in the no statistical adjustment was made for renal dysfunction, and it is certainly plausible that the observed associations general population have provided convincing evidence that reducing LDL cholesterol effectively decreases the were due to the fact that graft dysfunction causes hypertension. In a study that included statistical adjustment risk of IHD and lengthens survival. A meta-analysis of 5 randomized trials compared the effects of HMG-CoA for graft function, blood pressure was an independent predictor of graft survival in 277 renal transplant recipients reductase inhibitors to placebo in 30,817 patients [19] . Two of the trials included in the meta-analysis were [13] . In another study, hypertension was associated with graft failure among African Americans but not among primary prevention trials, while three studied patients with known coronary artery disease. Over a mean durawhites [14] . However, none of these studies examined the relationship between blood pressure and IHD per se. tion of 5.4 years of follow-up, treatment was associated with a 31% (95% confidence interval 26%-36%) reducIn a recent retrospective, uncontrolled, cross-sectional study of 287 patients, hypertension was more prevalent tion in the risk of coronary events and a 21% (14%-28%) reduction in all-cause mortality [19] . The reduction in risk in transplant recipients with coronary artery disease than in those without CAD [15] . We examined the relationwas similar in men and women, and in those 65 and older versus those younger than 65 years. Several secondary ship between blood pressure during the first year after renal transplantation and the subsequent development prevention trials also have shown that nicotinic acid, alone or in combination with clofibrate or colestipol, reduced of new IHD in a retrospective study of 1124 transplant recipients [16] . Although the qualitative relationship becoronary artery disease. Fibrates, for example, gemfibrozil and bezafibrate, also have reduced coronary artery distween blood pressure and IHD in transplant recipients was similar to that predicted by the Framingham Heart ease in secondary prevention trials. Because fibrates are more effective in reducing triglycerides and raising HDL Study equations [17] (Table 1) , the effect of blood pressure was not statistically independent of other risk factors than in reducing LDL, these latter trials have advanced the debate over the role of therapies targeting triglycerides [16] . Of course, a true effect of blood pressure on coronary artery disease might have been obscured by aggresand/or low HDL. Ongoing trials are studying whether reducing triglycerides and raising HDL reduces IHD in sive treatment of hypertension, other associated risk factors such as acute rejection, insufficient sample size, or a patients with normal or only modestly elevated LDL, a lipoprotein profile that is particularly common among found correlations between hyperlipidemia and IHD after transplantation [3, [35] [36] [37] [38] . We recently examined diabetics. In the meantime, current guidelines emphasize the importance of reducing LDL, and HMG-CoA reducthe relationship between lipid levels measured during the first year after transplantation and the subsequent tase inhibitors are clearly the most effective agents for reducing LDL cholesterol [20] .
development of new IHD in a retrospective study of 1124 transplant recipients [16] . The relationship between Hyperlipidemia is commonly defined using criteria set out by the National Cholesterol Education Program total cholesterol, HDL cholesterol, and IHD was similar in our transplant population compared with that pre-(NCEP) [20] . Low-risk total cholesterol and LDL cholesterol are Ͻ200 mg/dL and Ͻ130 mg/dL, respectively. dicted by the Framingham Heart Study equations (Table 1) [16] . Moreover, cholesterol (and triglycerides) High-risk total cholesterol and LDL are Ͼ240 mg/dL and Ͼ160 mg/dL. Low HDL is Ͻ40 mg/dL, and high fastcontinued to be independent predictors of IHD even after multiple risk factors, including acute rejection, were ing triglycerides are Ͼ200 mg/dL. In the National Kidney Foundation (NKF) Task Force on Coronary Vascular taken into account (Table 2) . Thus, the best current evidence strongly suggests that hyperlipidemia is associDisease (CVD), the prevalence of hyperlipidemia after renal transplantation was estimated by combining the reated with IHD in renal transplant recipients. The AST Guidelines recommend screening for hypersults of studies reporting the proportion of patients with elevated lipoproteins [21] . In 5 studies, 63% of 549 palipidemia at least once during the first six months and again at one year after transplantation with fasting total tients had total cholesterol Ͼ240 mg/dL [22] [23] [24] [25] [26] 27, [32] [33] [34] . Thus hyperlipidemia, especially increased LDL, is common after renal transplantation.
[11]. The NKF Task Force on CVD recently suggested that the NCEP Adult Treatment Panel II Guidelines be Although few studies have rigorously examined the relationship between hyperlipidemia and IHD after reused for the management of hyperlipidemia in patients with chronic renal disease, including renal transplant nal transplantation, several observational studies have tients. Moreover, a recent trial randomly allocated CsAtreated patients with hyperlipidemia to either continue CsA or switch to tacrolimus. Those who were switched to tacrolimus had a 25% reduction in LDL cholesterol recipients [21] . However, the NKF recommends that patients with chronic renal disease be considered in the compared to those who remained on CsA [39] . Clinicians also should consider substituting or discontinuing rapahighest risk category of the classification and treatment of hyperlipidemia. This approach would mean that transmycin in patients who have marked hyperlipidemia. A more difficult decision is whether to discontinue lowplant recipients should be managed as if they already had confirmed IHD (Fig. 1) . Thus, patients with LDL dose prednisone. Discontinuing prednisone is associated with an increased risk of acute rejection (10% to 15%). In Ͼ100 mg/dL should be started on a cholesterol reduction,
Step II American Heart Association diet, with goal LDL addition, although discontinuing prednisone can reduce total and LDL cholesterol somewhat, it also can reduce Ͻ100 mg/dL [20] . This diet calls for a saturated fat intake Ͻ7% of total calories and cholesterol Ͻ200 mg/day.
HDL. My own approach is to discontinue CsA in stable transplant recipients. Patients with LDL Ͼ130 mg/dL should be treated with both
Step II diet and a lipid-lowering drug, with goal Few studies have examined the safety and efficacy of combination therapy with lipid-lowering agents in renal LDL Ͻ100 mg/dL (Fig. 1) [20] . The drug of choice is an HMG-CoA reductase inhibitor. However, the dose of the transplant patients. Bile acid sequestrants can be used effectively in combination with HMG-CoA reductase HMG-CoA reductase inhibitor should be reduced by 50% in patients who also are taking a calcineurin inhibitor, inhibitors, but bile acid sequestrants generally should be avoided in patients with high triglyceride levels. Conas blood levels of HMG-CoA reductase inhibitors are increased in patients receiving calcineurin inhibitors. It cerns about reduced bioavailability of CsA have led to the recommendation that bile acid sequestrants not be is reasonable and most cost-effective to tailor the selec- administered at the same time as CsA. Fibric acid analogs cessation should be vigorously pursued in renal transplant recipients. Guidelines have been developed for can be used in combination with HMG-CoA reductase inhibitors, but the risk of myositis significantly rises with smoking cessation [44, 45] . Glucose intolerance. Epidemiologic studies strongly this combination, especially in CsA-treated patients. Nicotinic acid might be another option.
suggest that diabetes greatly increases the risk of IHD in the general population. In the Framingham Heart Cigarette smoking. Of course, no randomized controlled trials have yet proved that cigarette smoking causes IHD; Study, for example, diabetes increased the risk of coronary heart disease by 53% in men and 82% in women such trials would be unethical. Nevertheless, numerous large, observational studies have shown cigarette smok- (Table 1) [17]. Although it is generally accepted that diabetes increases the risk of IHD, whether intensive ing to be a major independent risk factor for IHD. In the Framingham Heart Study, for example, cigarette glycemic control reduces the risk of IHD has been more difficult to demonstrate. The Diabetes Control and Comsmoking increased the risk of coronary heart disease by 69% in men and 34% in women (Table 1) [17].
plications Trial revealed a (not statistically significant) tendency for IHD events to be reduced in the intensive Cigarette smoking appears to be as prevalent among renal transplant recipients as it is in the general populaglucose control group [46] . In the United Kingdom Prospective Diabetes Study, intensive glycemic control sigtion [40] . In retrospective, observational studies, cigarette smoking has been linked to IHD [35, 37, 40] , early nificantly reduced coronary heart disease events [47] . Thus, current evidence suggests that intensive glycemic mortality [40] [41] [42] , and graft failure [43] . We found that the risk associated with cigarette smoking in renal transcontrol reduces the incidence of IHD in the general population. plant recipients with IHD appeared to be greater than the risk predicted by the Framingham Heart Study. In-A growing number of renal transplant candidates have renal disease caused by diabetes. In addition, some padeed, cigarette smoking increased the risk of a major IHD event by almost twofold both in men and women tients who do not already have diabetes develop diabetes after transplantation. Corticosteroids as well as calcineu- (Table 1) [16]. Intervention is often effective, so smoking rin inhibitors contribute to the high incidence of postplantation. Despite a lack of evidence to support their efficacy in renal transplant recipients, a weight reduction transplant glucose intolerance. The incidence of new diabetes requiring insulin is probably about 5% in the first diet in obese patients and regular exercise in everyone should be encouraged given the potential for benefit and year after renal transplantation. The incidence of glucose intolerance not requiring treatment with insulin has not low risk.
Homocysteine. Several observational studies in the been well defined.
Several observational studies demonstrated that diageneral population have linked elevated plasma homocysteine levels to IHD [53, 54] . Results of ongoing ranbetes is a risk factor for IHD after renal transplantation. The risk of IHD from diabetes is severalfold higher than domized, controlled trials to determine whether lowering homocysteine reduces the incidence of IHD have not yet the risk from diabetes predicted by the Framingham Heart Study equations (Table 1) [16]. It is likely that been reported, however. Thus, it is not known whether homocysteine plays a pathogenetic role in IHD. The the factors important in the pathogenesis of diabetic nephropathy also are important in the pathogenesis of prevalence of hyperhomocysteinemia is high in renal transplant recipients compared to the general popula-IHD. Whether new-onset, post-transplant diabetes is also associated with an increased risk of IHD has not been tion. Moreover, renal transplant patients with IHD have higher homocysteine levels than do transplant patients examined in large, epidemiologic studies. However, posttransplant diabetes is associated with decreased graft without IHD [55, 56] . Although treatment with folic acid effectively reduces high homocysteine levels in renal survival [48, 49] .
Whether intensive glycemic control after renal transtransplant recipients [57, 58] , whether this approach reduces IHD will remain uncertain until randomized trials plantation will help prevent IHD is far from clear. Blood glucose control is likely to be more difficult to achieve are completed. Antioxidant vitamins. Studies in the general populasafely in patients who have long-standing diabetes and end-organ damage. Autonomic neuropathy causing detion have frequently reported an association between various indicators of oxidized lipoproteins and IHD [59]. layed gastric emptying and inability to sense hypoglycemia, for example, can make insulin dosing difficult.
However, several adequately powered, randomized, placebo-controlled trials in the general population have Pancreas or islet cell transplantation provides optimal glycemic control and might be a solution for some pafailed to demonstrate that anti-oxidant vitamins reduce IHD. Evidence exists for an increased prevalence of tients. Attempts should be made to prevent new-onset glucose intolerance by minimizing the use of corticostesmall, dense LDL in renal transplant recipients that are more prone to oxidative modification than are larger, roids and calcineurin inhibitors when possible.
Exercise and weight reduction. Diet and lack of reguless dense LDL [24] . Evidence also suggests that oxidized lipoproteins are more common in renal transplant recipilar exercise have been linked to IHD in observational studies in the general population. However, no randoments than in the general population [24] . However, given the negative results of randomized trials in the general ized controlled trials have conclusively demonstrated that a weight-reduction diet or regular exercise program population and the lack of any intervention trials in renal transplant recipients, treatment with anti-oxidant vitaameliorates IHD. In meta-analyses of randomized trials from the general population, single and multiple lifestyle mins does not appear to be warranted. Aspirin prophylaxis. Studies have shown that lowinterventions had modest effects on risk factors, and little effect on overall or cardiovascular mortality [50, 51] .
dose aspirin is effective in preventing recurrent cardiovascular events in patients with IHD and/or cerebral Guidelines developed by the National Heart, Lung, and Obesity is common after transplantation, in large part indicate that aspirin also is effective in patients without known CVD [60] , but the evidence supporting the use because of the use of corticosteroids. Sporadic evidence also suggests that regular exercise is rare among renal of aspirin in such patients is not as strong. The U.S. Preventive Services Task Force concluded that there was transplant recipients. In a retrospective study of 427 renal transplant recipients, body mass index Ͼ25 kg/m 2 was evidence neither for nor against the use of aspirin for primary prevention [65] . The American Diabetes Associan independent risk factor for cardiovascular disease [37] . Otherwise, few data show that obesity or a sedenation recommended aspirin in patients with diabetes who have other risk factors for CVD [62] . Because platelets tary lifestyle is an independent risk factor for IHD after renal transplantation. In addition, few data suggest that from renal transplant patients tend to have increased aggregability, it seems reasonable to recommend daily, diet or regular exercise is effective in achieving long-term weight reduction and mitigating IHD after renal translow-dose aspirin (65-85 mg/day) for renal transplant pa-tients with IHD [66, 67]. Perhaps we should treat other extend beyond their antihypertensive and cholesterollowering properties. Furthermore, both of these families high-risk patients as well; the risk is great enough to suggest that all renal transplant patients receive aspirin of drugs are renoprotective. Could you please comment on the merits of adopting a relatively liberal policy for prophylaxis unless it is contra-indicated. My own approach is to use low-dose aspirin in all renal transplant using these medications in renal transplant recipients? Dr. Kasiske: That is a very good point. A lot of data recipients, unless it is contraindicated.
Infections and inflammation. Recent evidence suggests from studies in the general population indicate that ACE inhibitors and HMG-CoA reductase inhibitors have benthat IHD is a systemic disease characterized by inflammation. Systemic inflammatory markers such as C-reaceficial effects on endothelial function. We like these drugs for these and other reasons, not just because they reduce tive protein and fibrinogen have been correlated with IHD events. One of the reasons that aspirin has been blood pressure and LDL cholesterol. In addition, up to one-fourth of our transplant population eventually deeffective in reducing IHD in patients with pre-existing cardiovascular disease might be its anti-inflammatory velops persistent proteinuria, for example, over 500 mg/ 24 h, and some of these patients become nephrotic. Data properties. However, few randomized controlled trials testing the efficacy of antimicrobial therapies in reducing suggest that we can reduce proteinuria using ACE inhibitors in renal transplant recipients. On the other hand, I IHD have been completed to date [68] . In renal transplant recipients, IHD has been associated with low serum know that some transplant centers are reluctant to use ACE inhibitors, because of the fear of provoking an albumin, which also might be a marker of systemic inflammation [16] . Until additional randomized controlled increase in serum creatinine. We don't feel that way, but we do watch serum creatinine closely after starting an trials are completed, it will be difficult to translate this and other observations supporting the role of infection ACE inhibitor. We also reduce the dose of HMG-CoA reductase inhibitors by about 50% in patients who are and systemic inflammation in IHD into useful intervenreceiving cyclosporine A or tacrolimus because of the tion strategies.
well-known interaction between these agents. Summary Dr. Madias: Left ventricular hypertrophy (LVH) is an independent risk factor for CVD. Do you have inforDramatic improvements in renal allograft survival mation on the magnitude of its role in renal transplant over the last 10 years have shifted the focus of postrecipients and recommendations for its diagnosis and transplant management from short-term considerations management? Also, could you comment on the recently to reduction of deaths due to IHD (and other causes) reported association between coronary artery calcificaover the long term. A growing body of evidence suggests tions, as detected by electron beam computed tomograthat the high incidence of IHD after renal transplantaphy, and the increased elemental calcium intake in young tion is in large part due to the high prevalence of tradiadult patients treated with dialysis [69]? It could repretional risk factors such as hypertension and hyperlipidsent yet another nontraditional risk factor for IHD in emia. It is neither feasible nor necessary to demonstrate ESRD patients and renal transplant recipients. that treating risk factors like elevated blood pressure Dr. Kasiske: Unfortunately, we do not have good data and LDL cholesterol is justified in reducing morbidity on LVH in our transplant population. We know that and mortality from IHD. Recent data suggest that the LVH often improves after transplantation, and there are incidence of IHD is declining in some centers [16] , likely a number of reasons for this. Before the introduction because of the use of new medications that effectively of erythropoietin, anemia was common in hemodialysis reduce factors for IHD. Further emphasis on managing patients. Correcting anemia with transplantation no doubt these risk factors, along with additional studies to idendecreased the incidence and severity of LVH in at least tify new prevention strategies, are needed if progress in some studies from that era. Volume overload also can reducing this major cause of death in transplant patients masquerade as LVH, and volume status can improve afis to continue. ter transplantation. Whether other "uremic" factors can be improved with transplantation, and thereby cause a re-QUESTIONS AND ANSWERS gression of LVH, is still debated. As you pointed out, Dr. Nicolaos E. Madias (Executive Academic Dean, electron beam tomography studies show a high incidence Tufts University School of Medicine, Boston, Massachuof coronary artery calcification in hemodialysis patients setts, USA): Endothelial dysfunction caused by immuno- [69] . Of course, maintaining normal calcium and phossuppressive agents might be one of the nontraditional phorus levels in hemodialysis patients is always a chalrisk factors that contribute to IHD after renal translenge. In contrast, stable renal transplant recipients plantation. As you know, ACE inhibitors and HMGusually have normal calcium and phosphorus levels. CoA reductase inhibitors defend the structural and funcWhether the incidence of coronary artery calcification after transplantation declines is unknown. Of course, the tional integrity of the vasculature via mechanisms that clinical significance of coronary calcifications is also not unclear. Perhaps systemic inflammation plays an important role, for example, inflammation from the dialysis known. They could contribute to the pathogenesis of coronary lesions or they could be an epiphenomenon of membrane, infections, or other factors. Whether a high calcium-phosphorus product is important, and whether little functional significance.
Dr. Hamid Rabb (Hennepin County Medical Center, we might help reduce the incidence of CVD by avoiding calcium-containing phosphate binders are both imporUniversity of Minnesota School of Medicine, Minneapolis, Minnesota): Recent evidence has implicated inflamtant questions without answers at this time. Dr. Madias: How much information do we have remation in the pathogenesis of atherosclerotic CVD. In fact, data indicate that T-cells themselves could be major garding the incidence of CVD in relatively comparable populations of dialysis and transplant patients? Do we mediators of ischemic reperfusion injury and potentiate myocardial infarction. Activation of T-cells directed at have any good data on CVD in waiting list patients? Dr. Kasiske: Robert Wolfe and coworkers compared the allograft, as we see in our transplant patients, could prime T-cells to promiscuously damage the myocardium.
the overall mortality of transplant recipients with those still on the waiting list [70] . Mortality was higher for paIs there any known link between T-cells and IHD after transplantation?
tients on the transplant waiting list compared to transplant recipients. Of course, the assumption was made that Dr. Kasiske: I am not aware of any studies addressing this directly, but it is a very interesting hypothesis. Ineveryone who was on the waiting list was a transplant candidate. Unfortunately, no data corroborate this asdeed, the general hypothesis that systemic inflammation plays an important role in the pathogenesis of atherosclesumption, and it is likely that an unknown proportion of waiting list patients were "on hold." Nevertheless, the rotic CVD is a fascinating one. Unfortunately, almost all the data supporting it are circumstantial. However, I
difference in mortality between waiting list and transplant patients was very large, and it is therefore unlikely believe that it is a very plausible hypothesis, and perhaps mechanisms like those you are suggesting could be imto be artifactual. Although not addressed in this study, it is likely that much of the difference in mortality between portant. We have noted that low serum albumin after transplantation is associated with subsequent IHD events.
these two populations is due to a difference in CVD events. At the American Society of Nephrology meeting It is possible that hypoalbuminemia acts as a marker of systemic inflammation, similar to elevations in C-reactive in Toronto, October 13-16, 2000, we presented a preliminary analysis demonstrating that the incidence of CVD protein. On the other hand, we failed to find a statistically significant association between CMV infections and IHD is indeed higher among patients on the waiting list compared to transplant recipients. It is remarkable that dein our transplant population. Nevertheless, the idea that a chronic inflammatory state, for example, from infecspite the very high prevalence of CVD risk factors after transplantation, transplant recipients still seem to have tions or subclinical rejection, primes T-cell involvement is a very good one. a lower incidence of CVD relative to comparable dialysis patients. That really suggests to me that there is someDr. Mark Rosenberg (University of Minnesota School of Medicine): As you know, we do not do a good job of thing going on in the dialysis population that is very bad with respect to CVD. controlling risk factors in our dialysis patients. plant screening and prophylactic intervention on outcomes [2] . The study suggested that revascularization of Dr. Kasiske: Certainly CVD is present in a large number of patients at the time of transplantation. However, asymptomatic diabetic patients with significant coronary artery stenosis reduced the number of cardiac events in the Kaplan-Meier curve showing the accumulation of IHD events after transplantation [3] , it is apparent that compared to medical management. If this result is true, it provides a strong argument for screening as part of the the risk for new events is still accruing even 15 to 20 years after transplantation. It is unlikely that these late pre-transplant evaluation. Unfortunately, the number of patients in the study was very small. In addition, optimal events are due to pre-transplant IHD. It is more plausible that CVD is acquired both before and after transplantamedical management has changed since the time of the study; if the study were done today, a beta-blocker might tion. Your point is valid, and certainly risk factor management before transplantation in the dialysis populabe selected instead of a calcium antagonist, for example. It is also unfortunate that revascularization included both tion is important. However, the factors that cause a very high incidence of CVD in the dialysis population are still bypass surgery and angioplasty, procedures that might have very different success rates in this population. Where conscious of risk factors and are adopting healthier lifeshould we go from here?
styles. In addition, we have better antihypertensive mediDr. Kasiske: I believe that a large-scale, randomized, cations and better lipid-lowering agents, and we have controlled trial is warranted to examine outcomes after been using these aggressively in our transplant populascreening versus no screening in a population of hightion. The other thing that appears to have changed over risk patients. Screening could be done with a noninvasive the years, at least in our institution, is the level of awarestress test followed by angiography and revascularization ness of IHD and the aggressiveness of screening and as indicated by defined criteria. Appropriate inclusion intervention. We have been doing a lot more screening and exclusion criteria could be specified to avoid includfor IHD, and we have been doing a lot more intervention ing patients in whom such screening is necessary. Such a with bypass surgery, angioplasty, and stent placement. study also would need to address the issue of re-screening All of these could contribute to the reduced incidence while patients are on the waiting list. Of course, the study of IHD events. In terms of screening after transplantawould have to be designed in such a way that costs were tion, that is also something we have discussed a lot lately. not prohibitive.
Should as high a risk factor as in dialysis patients? How is this Dr. Kasiske: These are both very good questions. Is managed? the reduction in IHD from prophylactic aspirin seen in Dr. Kasiske: We know that homocysteine correlates randomized trials in the general population due not only with IHD after transplantation. We also know that one can to the antiplatelet effect of aspirin but also to an antilower homocysteine levels with a combination of vitainflammatory effect? If there were a higher inflammatory mins B 6 , B 12 , and folate. Unfortunately, we are still waitstate after renal transplantation, for whatever reasons, ing for the results of randomized trials that demonstrate would anti-inflammatory medications be beneficial? Unlowering homocysteine reduces IHD events. One could fortunately, no clinical trial data answer this question.
argue that taking vitamins is innocuous, so that we should Obviously, the problem with using nonsteroidal antibe doing this even without good data from clinical trials. inflammatory medications is the potential for adverse On the other hand, transplant patients already take muleffects, for example, an increase in serum creatinine, intiple medications, and adding more pills would increase terstitial nephritis, gastrointestinal bleeding. Currently, the risk of noncompliance. I would hate to see a transwe recommend the use of low-dose, prophylactic aspirin, plant patient miss doses of immunosuppressive medicafor example, approximately 80 mg/day, in transplant retions because we complicated the drug regimen by addcipients at risk for CVD. When we have patients with ing a number of medications of unproven benefit. persistent proteinuria (Ͼ1 g/24 h), we first try using an Dr. Madias: Should the recommendations that you ACE inhibitor to control the proteinuria, and we genermade, at least the relevant ones, be amended for pediatally avoid using nonsteroidal anti-inflammatory agents ric transplantation? in this setting.
Dr. Kasiske: I do not know. Cardiovascular risk facDr. Madias: Could you please expand on the most tors have only recently received the attention of pediatric plausible reasons for the declining incidence of IHD obnephrologists. With improved outcomes after renal transserved in some centers? Also, could you comment on plantation in the pediatric age group, more of these pathe role of screening for IHD after transplantation? tients are surviving into adulthood. It is plausible that Dr. Kasiske: It is very heartening to see that the inciwe will see more IHD in young adults who have had a dence of IHD has been declining in our transplant poputransplant for an extended period. So I think there is a lation. It would be nice to know why this is so, but we growing need for risk factor management in the pediatric can only speculate. Of course, the incidence has been age group. Unfortunately there are not a lot of data in falling in the general population, and the reduction has this area. been attributed to both better risk factor management Dr. Aaronson: Is the rate of IHD different in patients and better screening and treatment of IHD in the general population. Perhaps our transplant recipients are more who have received a kidney transplant versus a kidney/ pancreas transplant? Is the kidney/pancreas transplant levels of low-density lipoprotein cholesterol. The advantage of this approach would be to avoid the common cardioprotective?
Dr. Kasiske: The problem that we have with underproblem of undertreatment. I think that would be a reasonable approach, one worth considering. standing the benefits of pancreas transplantation is that there have never been any randomized controlled trials.
Dr. Madias: If I recall correctly, in your analysis, bilateral nephrectomy for PKD increased the risk for IHD, Any arguments about the effects of pancreas transplantation on microvascular or macrovascular disease are highly but the same procedure for non-PKD patients was associated with decreased risk. Could you please comment speculative. Pancreas transplant recipients are highly selected patients. I do not think you can adequately adjust on this issue? Dr. Kasiske: Having a bilateral nephrectomy before for this fact statistically by using multivariate analysis. I think the question is impossible to answer in the absence transplantation, a practice that was more common 20 years ago, was associated with less IHD. This might result of clinical trials. Unfortunately, the obstacles to conducting such a trial might be insurmountable.
from better blood pressure control. However, when we looked for interactions in the analysis, we found that Dr. Madias: You mentioned some data indicating an inverse relationship between blood pressure in renal patients who had polycystic kidney disease and underwent bilateral nephrectomy had an increased risk of transplant recipients and graft survival. Did this relationship feature a threshold value below which no benefit IHD. I suspect that many of those polycystic kidney disease patients had bilateral nephrectomy because they on survival could be discerned? Also, were any classes of antihypertensive medications associated with increased had very large kidneys. Polycystic kidney disease by itself was not a risk factor for IHD; it was only a risk factor benefit?
Dr. Kasiske: The Collaborative Transplant Study regamong patients who had bilateral nephrectomy. In analyses such as this, the possibility always exists that one or istry appears to show a simple linear relationship between blood pressure and graft failure [71] . There is no more of the several risk factors were statistically significant only by chance. However, there is an independent J-shaped curve, and one cannot see a threshold effect of blood pressure on patient or graft survival. Few data on study that also reported that patients with polycystic kidney disease have an increased risk of IHD after transthe relative merits of different antihypertensive agents in renal transplant recipients are available, and certainly plantation [72] . This makes it more likely that ours was not a chance finding. no data from large, randomized controlled trials that have measured outcomes in this population. In our reDr. Rosenberg: How much can we reduce the CVD burden by selecting immunosuppressive agents with mincent observational study of risk factors for IHD, we found that patients who were taking dihydropyridine imal adverse effects on CVD risk factors? I was struck by a recent article looking at cyclosporine A versus tacalcium antagonists one year after transplantation were at increased risk for subsequent IHD events [16] . No crolimus that showed that both blood pressure and lipids were decreased with tacrolimus [73] . The other issue is other antihypertensive medication was associated with IHD. This was a retrospective analysis, and there could whether steroid avoidance can decrease cardiovascular risk factors. be several reasons for this association. For example, the patients who were already at high risk for IHD might Dr. Kasiske: Unfortunately, most of the studies examining the effects of changes in immunosuppression on have been more likely to be treated with dihydropyridine calcium antagonists. Nevertheless, the fact that other CVD risk have only followed patients over a relatively short period and have only measured one or two cardiostudies in the general population have raised concerns about calcium antagonists and IHD makes this result vascular risk factors. While it might not be feasible to conduct trials to examine the incidence of CVD events disconcerting.
Dr. Shakeel Anjum (Nephrology Fellow, University for all different combinations of immunosuppression, it is nevertheless important to at least examine the effects of Minnesota Division of Nephrology): Considering that renal transplant patients are at high risk to begin with, of changes in immunosuppression on all of the wellestablished CVD risk factors over a sufficiently long peand that they will be on immunosuppression after transplantation, would it be reasonable to give everyone a riod by intention-to-treat analysis. For example, it might be easy to show that after prednisone withdrawal, the statin after transplantation?
Dr. Kasiske: The prevalence of hyperlipidemia and serum cholesterol goes down and blood pressure improves. However, what you also have to factor into the the risk for IHD are so high that one can make an argument that every patient should be started on an CVD risk equation is the percentage of patients who have an acute rejection. In those patients, graft dysfunc-HMG-CoA reductase inhibitor as part of the initial immunosuppression protocol, or at least at the time of tion or the higher doses of steroids required to treat rejection can adversely affect CVD risk. Perhaps the hospital discharge after transplantation. The agent then could be stopped if the recipient subsequently had low best approach is to randomize patients to different immu-
